Inter- and intraindividual variability of riluzole serum concentrations in patients with ALS

Journal of the Neurological Sciences

Volumn 191, Issue 1-2, 2001, Pages 121-125

  Groeneveld, G J ^a   Van Kan, H J M ^b   Sastre Torano J ^b   Veldink, J H ^a   Guchelaar, H J ^b   Wokke, J H J ^a   Van Den Berg, L H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Amyotrophic lateral sclerosis; CYP1A2; Drug metabolism; Polymorphism; Riluzole; Treatment

Indexed keywords

RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; ASTHENIA; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIET; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG METABOLISM; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INCIDENCE; MALE; NAUSEA; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; VERTIGO;

ADULT; AGE FACTORS; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANALYSIS OF VARIANCE; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; REPRODUCIBILITY OF RESULTS; RILUZOLE; SMOKING; VARIATION (GENETICS);

EID: 0035886647     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(01)00613-X     Document Type: Article

References (15)

1. The pharmacology and mechanism of action of riluzole
2. Neuroprotective effects of riluzole in ALS CSF toxicity
3. Protective effect of riluzole on excitatory amino acid-mediated neurotoxicity in motoneuron-enriched cultures
4. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity
5. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis
6. A controlled trial of riluzole in amyotrophic lateral sclerosis
7. A confirmatory dose-ranging study of riluzole in ALS
8. Single- and multiple-dose pharmacokinetics of riluzole in white subjects
9. Population pharmacokinetics of riluzole in patients with amyotrophic lateral sclerosis
10. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro
11. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity
12. Pharmacogenetics and adverse drug reactions
13. Riluzole
14. Riluzole: A new agent for amyotrophic lateral sclerosis